Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
January 31, 2023 8:00 AM
NEWARK, Calif., January 31, 2022 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Wednesday, February 8, 2023, at 9:35 a.m. ET, being held in New York, NY.